High-Density Lipoprotein: Structural and Functional Changes Under Uremic Conditions and the Therapeutic Consequences by unknown
High-Density Lipoprotein: Structural
and Functional Changes Under Uremic
Conditions and the Therapeutic
Consequences
Mirjam Schuchardt, Markus To¨lle, and Markus van der Giet
Contents
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425
2 Chronic Kidney Disease: Epidemiology and Pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . 426
3 Dyslipidemia, Lipid-Modulating Therapy, and Cardiovascular Risk in CKD Patients . . 428
3.1 Dyslipidemia in CKD Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
3.2 Lipid-Modulating Therapy in CKD Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
3.3 Protective Effects of HDL on the Kidney . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
4 Structural and Functional Modifications of HDL in CKD Patients . . . . . . . . . . . . . . . . . . . . . . . 436
4.1 Dysregulation of Proteins in HDL Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436
4.2 Changes of HDL Apolipoproteins (Modifications and Levels) . . . . . . . . . . . . . . . . . . . . . 438
4.3 Loss of Protective Proteins or Lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 440
4.4 Increase of Molecules within HDL with a Fatal Function in the Vascular Wall . . . 441
5 Possibility of Functional Restoration of HDL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 442
6 Laboratory Tests to Measure HDL Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 443
Conclusion and Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 444
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 444
Abstract
High-density lipoprotein (HDL) has attracted interest as a therapeutic target in
cardiovascular diseases in recent years. Although many functional mechanisms
of the vascular protective effects of HDL have been identified, increasing the
HDL plasma level has not been successful in all patient cohorts with increased
cardiovascular risk. The composition of the HDL particle is very complex and
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includes diverse lipids and proteins that can be modified in disease conditions. In
patients with chronic kidney disease (CKD), the accumulation of uremic toxins,
high oxidative stress, and chronic micro-inflammatory conditions contribute to
changes in the HDL composition and may also account for protein/lipid
modifications. These conditions are associated with a decreased protective
function of HDL. Therefore, the HDL quantity and the functional quality of
the particle must be considered.
This review summarizes the current knowledge of dyslipidemia in CKD
patients, the effects of lipid-modulating therapy, and the structural modifications
of HDL that are associated with dysfunction.
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ROS Reactive oxygen species
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SHARP Study of Heart and Renal Protection
S1P Sphingosine-1-phosphate
sPLA2 Secretory phospholipase type 2
SR-BI Scavenger receptor BI
VA-HIT Veterans’ Affairs High-Density Lipoprotein Intervention Trial
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1 Introduction
Plasma lipoproteins are composed of non-covalent aggregates of different lipids
and proteins. They transport water-insoluble substances in the blood by building
micelle-like structures. These structures are classified by their density into the
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following groups: very low-density lipoprotein (VLDL), intermediate-density lipo-
protein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).
In previous years, several clinical studies have found that HDL cholesterol
(HDL-C) plasma levels were inversely correlated with cardiovascular risk, whereas
high LDL-C levels were related to increased cardiovascular mortality
(Di Angelantonio et al. 2009; Gordon et al. 1977; Mori et al. 1999). Initially, due
to the crucial role of HDL in reverse cholesterol transport (RCT), HDL was
associated with a decreased cardiovascular risk. Therefore, the theory of the
“good HDL” and “bad LDL” emerged. Further studies, primarily in vitro or animal
studies, identified the pleiotropic cardiovascular protective effects of HDL in
addition to its RCT function: HDL has anti-atherosclerotic, anti-inflammatory,
antioxidative, antithrombotic, and endothelial-protective properties (Navab
et al. 2011). Accordingly, there is growing interest in the study of HDL metabolism
and the cellular and the molecular signaling pathways involved in its vascular
protective effects.
Therefore, enhancing HDL plasma levels has been a principal approach for the
reduction of cardiovascular risks in different patient cohorts. Pharmacologically
active substances, such as cholesterol ester transfer protein (CETP) inhibitors,
fibrates, and niacin, have been tested in large clinical trials to evaluate the occur-
rence of cardiovascular endpoints (Longenecker et al. 2005; van Capelleveen
et al. 2014). However, raising HDL-C plasma levels did not protect against cardio-
vascular events in all patient cohorts tested. In addition, despite a significant
HDL-C increase in patients, large clinical trials were terminated because of a
lack of positive effects or, in some cases, an increase in the rate of cardiovascular
events.
These findings indicate that a better understanding of lipoprotein modifications
in disease conditions is necessary to establish possible indications and target
mechanisms in the therapy of cardiovascular diseases. Patients with chronic kidney
disease (CKD) suffer from a dramatic increase in cardiovascular morbidity and
mortality. The disease condition is associated with dyslipidemia and/or
modifications in lipoprotein composition and function (Keane et al. 2013; Vaziri
2006).
This review summarizes current knowledge regarding the structural and func-
tional changes of HDL in the context of renal dysfunction. A brief overview of
CKD epidemiology and pathophysiology is presented, followed by aspects of
dyslipidemia and its therapy in CKD patients. Subsequently, CKD-dependent
structural and functional changes of HDL are summarized.
2 Chronic Kidney Disease: Epidemiology
and Pathophysiology
Kidney disease is defined as an abnormality of kidney structure or function. The
criteria for abnormalities include: albuminuria, urine sediment abnormalities, elec-
trolyte and other abnormalities due to tubular disorders, abnormalities detected by
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histology or imaging, and history of kidney transplantation (Levey et al. 2005).
Kidney disease can occur abruptly, and it can either resolve or become chronic.
CKD is defined as kidney damage that persists for more than 3 months (Levey
et al. 2005). CKD is one of the major medical concerns associated with premature
morbidity and mortality, especially due to cardiovascular complications. The epi-
demic of CKD is globally driven by demographic aging, as well as an increase in
other risk factors leading to CKD (e.g., diabetes mellitus, hypertension, and
obesity).
CKD is divided into different stages, which are summarized in Fig. 1, based on
the glomerular filtration rate (GFR) (Levey et al. 2005). CKD patients have a high
occurrence of cardiovascular disease. In recent years, several studies have
implicated an inverse correlation of kidney function and cardiovascular mortality
(Tonelli et al. 2006). Thereby, the cardiovascular phenotype of the CKD population
is heterogeneous, and the cardiovascular risk depends on the CKD stage. In addition
to traditional risk factors, such as hypertension, diabetes mellitus, and smoking,
nontraditional risk factors also contribute to cardiovascular diseases. In CKD
patients, the nontraditional risk factors of anemia and enhanced oxidative stress
or uremic toxins play a major role in cardiovascular disease progression
(Mizobuchi et al. 2009). Under normal conditions, uremic toxins are cleared by
the kidneys, and many of these toxins have been recently identified (Duranton
et al. 2012). Uremic toxins are classified as water-soluble molecules with low
molecular weight (e.g., uric acid), middle molecules (e.g., parathyroid hormone),
and protein-bound toxins (e.g., hippuric acid) (Duranton et al. 2012). A number of
different uremic toxins are elusive, and biological functions have not been
identified for all toxins. Clinical studies have shown that cardiovascular morbidity
and mortality in CKD patients are associated with uremic toxin accumulation,
which leads to a progression of vascular alterations. Recently, Moradi
et al. summarized the influence of uremic toxins on vascular cells and pathological
pathways in the vascular wall (Moradi et al. 2013). The activation of leukocytes;
Fig. 1 Categories of chronic renal failure. CKD categories were divided into subgroups according
to KDIGO 2013
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endothelial damage, for example, by the disruption of glycocalyx and production of
reactive oxygen species (ROS); the proliferating effects on smooth muscle cells;
and platelet activation are only some of the described effects (Moradi et al. 2013).
In addition, uremic toxins influence lipoprotein modifications. Urea induces the
formation of carbamylated LDL (cLDL) (Apostolov et al. 2010). Some uremic
toxins are lipid-bound and may occur in a different subfraction of lipoproteins.
Additionally, HDL function may be affected by the accumulation of uremic toxins.
Nonetheless, further studies are necessary to characterize the impact of different
compounds on cardiovascular outcome and the precise signaling pathways
involved. The therapeutic goal should be to remove the solutes associated with
the highest cardiovascular risk to minimize fatal cardiovascular outcomes in
patients with CKD. To date, cardiovascular morbidity in patients with CKD
remains high despite the utility of dialysis and renal transplantation (Foley
et al. 1998).
3 Dyslipidemia, Lipid-Modulating Therapy,
and Cardiovascular Risk in CKD Patients
In the general population, plasma lipid levels correlate with the level of cardiovas-
cular risk (Di Angelantonio et al. 2009). Increased LDL-C levels have been
associated with cardiovascular mortality. LDL-C is a primary risk biomarker for
cardiovascular disease in the general population; however, it loses its prognostic
association in CKD patients (Kilpatrick et al. 2007), especially for patients with
end-stage renal disease (ESRD) (Baigent et al. 2011; Kovesdy et al. 2007). In
addition, traditional risk factors, such as hypercholesterolemia, hypertension, and
obesity, no longer appear to be related to the level of cardiovascular risk in ESRD
patients. One explanation might be the accumulation of nontraditional risk factors
in CKD patients (Appel 2004; Coresh et al. 1998; Muntner et al. 2004). Presumably,
the complexity of traditional and nontraditional risk factors determines patient
outcome. An alternative explanation may be that patient outcome is determined
by the numerous quantitative and qualitative lipid abnormalities in triglycerides,
phospholipids, and lipoproteins that are observed in CKD patient cohorts (Keane
et al. 2013; Vaziri 2006).
3.1 Dyslipidemia in CKD Patients
Several studies have demonstrated a characteristic switch in the lipid phenotype at
different stages of CKD. Data from the “Multi-Ethnic Study of Atherosclerosis”
(MESA) have indicated an elevation of triglyceride-rich lipoproteins (Lamprea-
Montealegre et al. 2013). Triglyceride-rich VLDL or other apoB-rich lipoproteins
accumulate in patients with ESRD as a consequence of increased triglyceride levels
(Vaziri and Norris 2011). The VLDL particle increase depends on the CKD stage
and is aggravated by a decline in kidney function (Lamprea-Montealegre
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et al. 2013). Hypertriglyceridemia is caused by reduced lipoprotein lipase (LPL)
levels (Vaziri 2006; Vaziri et al. 2012) and results in the limited delivery of
triglyceride-rich fuel lipoproteins to adipocytes and myocytes (Vaziri et al. 2012).
The enrichment of triglyceride-containing lipoprotein particles results in a higher
susceptibility to oxidative modifications. These particles are highly
pro-inflammatory (Vaziri 2013). In addition, other apoB-rich lipoproteins, such as
small dense LDL or IDL-C, are commonly increased in patients with CKD (Saland
and Ginsberg 2007; Vaziri 2006). The reduced clearance rate of LDL particles
contributes to the increase in LDL levels (Ikewaki 2013).
Lipoprotein a (Lp(a)), which consists of apoA and apoB and is similar to LDL-C,
is increased in CKD patients (Longenecker et al. 2005; Muntner et al. 2004). Lp
(a) serves as an independent biomarker that predicts cardiovascular complications
(Jacobson 2013; Thompson and Seed 2013).
Dyslipidemia is further enhanced by hyperparathyroidism, which frequently
occurs in CKD patients (Moe and Sprague 2012). Normal lipid metabolism depends
on proper parathyroid function, and hyperparathyroidism tends to result in hypertri-
glyceridemia (Liang et al. 1998) as well as in a deficiency in lipid metabolism
enzymes, such as hepatic lipase and LPL (Klin et al. 1996). The enrichment of
apoB-containing lipoproteins is correlated with decreased HDL-C levels (Saland
and Ginsberg 2007; Vaziri 2006).
The lipid profile is altered in CKD patients compared with healthy subjects and
differs depending on the stage of CKD progression (e.g., stage I to V, pre/post-
dialysis, and time on dialysis) and the dialysis procedure (e.g., hemodialysis
(HD) or peritoneal dialysis (PD)). As a consequence, the lipid profiles of the
CKD population are heterogeneous. Extrinsic factors, including drug administra-
tion for kidney disease and associated disorders (hypertension, diabetes mellitus,
and malnutrition), contribute to dyslipidemia in this patient cohort.
To overcome the complex dyslipidemia in CKD patients, diverse clinical trials
have addressed the influence of lipid-modulating therapies on cardiovascular
outcomes. The results of these therapies in the general population suggest that the
incidence of cardiovascular events in CKD patients is expected to decrease (van
Capelleveen et al. 2014).
3.2 Lipid-Modulating Therapy in CKD Patients
Currently, drugs that treat dyslipidemia are in use or under investigation. Statins,
which primarily lower the LDL-C level; peroxisome proliferator-activated receptor
(PPAR) agonists; inhibitors of lipid metabolism (CETP, niacin); and apoAI
mimetics have been evaluated in preclinical and/or clinical studies. The currently
established lipidemic drugs have been reviewed elsewhere; therefore, this article
summarizes aspects of therapy related to CKD. Although lipid-modulating
therapies have had a positive impact on the cardiovascular outcome in patients
with normal kidney function, the effect in CKD patients has been disappointing.
These observations have originated predominantly from statin trials.
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Statin treatment leads to a reduction in LDL-C through the inhibition of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the initial
enzyme in endogenous cholesterol biosynthesis. In several clinical trials, it has
been clearly demonstrated that for patients without renal disease, a reduction of
LDL-C upon statin therapy is associated with a decreased cardiovascular mortality
rate (The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group 1998; Scandinavian Simvastatin Survival Study Group 1994; Baigent
et al. 2005; Collins et al. 2003; LaRosa et al. 2005; Sever et al. 2003). Due to the
substantially high cardiovascular risk in CKD patients, the effect of statin therapy
was also evaluated in three large clinical trials (>1,000 patients included): the
“Deutsche Diabetes Dialyse Studie” (4D) (Wanner et al. 2005), “A Study to
Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assess-
ment of Survival and Cardiovascular Events” (AURORA) (Fellstrom et al. 2009a),
and “Study of Heart and Renal Protection” (SHARP) (Baigent et al. 2011). The
“Prevention of Renal and Vascular End-Stage Disease Intervention Trial”
(PREVEND-IT) (Asselbergs et al. 2004; Brouwers et al. 2011) has also addressed
the effect of statin therapy in a smaller cohort (<1,000 patients) but included a
longer follow-up period. The “Assessment of LEscol in Renal Transplantation”
(ALERT) (Holdaas et al. 2003) trial investigated cardiovascular outcomes in renal
transplant recipients. The 4D study consisted of a randomized control trial that
examined Western HD patients with diabetes (Wanner et al. 2005). No benefits in
the primary endpoints were observed in a follow-up period of approximately
4 years (Wanner et al. 2005) (Table 1). A subsequent subgroup analysis of the 4D
study cohort showed a reduction in cardiovascular disease after statin treatment in
patients with LDL-C >145 mg/dL (Marz et al. 2011). The 4D trial with 1,225
patients was followed by the larger AURORA trial, which enrolled 2,776 HD
patients with and without diabetes mellitus. Nonetheless, the reduction in LDL-C
that was observed did not have an effect on cardiovascular outcomes (Fellstrom
et al. 2009a). Another large randomized trial, the SHARP trial, enrolled HD patients
and CKD patients in stages III to V: (Baigent et al. 2011). The combination therapy
of simvastatin and ezetimibe lowered the LDL-C level but did not reduce the
overall vascular mortality (Baigent et al. 2011). However, the risk for atheroscle-
rotic events was reduced in a wide range of CKD patients (Baigent et al. 2011). The
longest follow-up period, up to 9.5 years, was in the PREVEND-IT trial
(Asselbergs et al. 2004; Brouwers et al. 2011). Here, patients with
microalbuminuria were enrolled and treated with pravastatin and fosinopril. In
the follow-up period of 46 months, pravastatin treatment had no effect on cardio-
vascular endpoints (Asselbergs et al. 2004). The extended follow-up period of
9.5 years showed that elevated urinary albumin excretion was associated with
increased cardiovascular morbidity and mortality (Brouwers et al. 2011).
Thus, the large clinical trials examining statin therapy in CKD patients failed to
show a significant reduction in overall cardiovascular mortality for patients
undergoing dialysis treatment (Table 1). Based on the data from the US Renal
Data System, the majority of cardiovascular deaths in CKD patients are due to
chronic heart failure and are not influenced by statin treatment (Collins et al. 2013).
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Therefore, other uremia-related pathways and/or the previously existing vascular
damage may contribute to the increase in cardiovascular risk. A trial that
investigated the effect of statin therapy in renal transplant recipients observed
similar effects. In the ALERT trial (Holdaas et al. 2003), statin therapy reduced
the LDL-C plasma concentration in treated patients (Holdaas et al. 2003). Although
fewer cardiac deaths and nonfatal MIs were observed, no significant reduction in
the primary endpoint was achieved (Holdaas et al. 2003).
Based on the findings of the current clinical trials with CKD patients, the
therapies tested had either no real impact on cardiovascular outcome or resulted
in fatal effects (Kilpatrick et al. 2007). Interestingly, despite a robust reduction in
the LDL-C level, only negative or neutral effects on acute cardiovascular events
were measured (Baigent et al. 2011; Fellstrom et al. 2009b; Wanner et al. 2005).
Effective prevention of cardiovascular events was only documented in patients with
mild to moderate CKD (Baigent et al. 2011).
In addition to statins, which primarily lower LDL-C plasma levels, other lipid-
modulating drugs are currently used in non-renal-insufficient patients. Here, differ-
ent targets in HDL metabolism have been identified to overcome dyslipidemia.
Initial studies addressed the effect of enzyme inhibition on lipid metabolism, such
as CETP inhibition. PPAR agonists, niacin, and apoAI mimetics are other thera-
peutic options that have been tested in clinical and/or preclinical studies. However,
these studies often excluded patients with CKD from recruitment. Therefore,
further studies are necessary to determine the effects of these therapies on patients
with renal insufficiency.
CETP is responsible for the shuttling of cholesteryl esters between HDL and
apoB-containing lipoprotein particles. Inhibition of this enzyme results in a dra-
matic increase in HDL levels. Torcetrapib was the first CETP inhibitor examined in
a large clinical trial, “Investigation of Lipid Level Management to Understand Its
Impact in Atherosclerotic Events” (ILLUMINATE) which included approximately
15,000 patients (Barter et al. 2007). The treatment increased the HDL concentration
by more than 50 % (Barter et al. 2007). However, the study was prematurely
terminated because an increased risk of cardiovascular events was observed (e.g.,
increase in arterial blood pressure) (Barter et al. 2007). In the ILLUMINATE trial,
patients with severe CKDwere not enrolled. The mean eGFR in patients included in
the study was 79.5 ml/min/1.73 m2 with creatinine concentration of 1 mg/dL
(Barter et al. 2007). In subsequent trials with other CETP inhibitors, which
attempted to overcome the off-target effects of torcetrapib, CKD patients were
excluded. The “Determining the Efficacy and Tolerability of CETP Inhibition with
Anacetrapib” (DEFINE) study (Cannon et al. 2010) investigated anacetrapib, and a
key exclusion criteria in this study was an eGFR <30 ml/min/1.73 m2 or severe
renal impairment (Cannon et al. 2010). In the dal-OUTCOMES trial with
dalcetrapib (Schwartz et al. 2009, 2012), the exclusion criteria was a creatinine
level of>2.2 mg/dL (Schwartz et al. 2009). For the “Randomized Evaluation of the
Effects of Anacetrapib Through Lipid-Modification” (REVEAL) study, patient
recruitment is ongoing, and the study is expected to be completed in 2017 (Gutstein
et al. 2012). On the basis of the current CETP inhibitor studies, the effects of CETP
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inhibition on cardiovascular mortality cannot be determined, and patients with
severe CKD were excluded from all studies.
Niacin treatment most effectively raises HDL-C levels and decreases triglycer-
ide, LDL-C, and Lp(a) levels. The mechanism underlying the influence of niacin on
HDL metabolism is unknown (Linsel-Nitschke and Tall 2005). The beneficial
effects on lipoprotein levels and the corresponding cardiovascular outcome have
been described in several small-scale clinical trials. Unfortunately, the large-scale
trials AIM-HIGH (AIM-HIGH Investigators 2011; Boden et al. 2011) and HPS2-
THRIVE (2013), in which patients were treated with niacin in combination with a
statin, were prematurely terminated because of a high prevalence of side effects. In
both studies, no patients with severe CKD were included. In AIM-HIGH, the mean
eGFR was 82.8 ml/min/1.72 m2 (2011), and in HPS2-THRIVE, severe renal
insufficiency was an exclusion criteria for patient recruitment (2013).
The family of PPAR transcription factors is involved in the regulation of fatty
acid metabolism and influences lipid levels. The family consists of three members:
PPAR-α, PPAR-γ, and PPAR-δ. PPAR-γ agonists, such as rosiglitazone and
pioglitazone, are high-affinity agonists at the receptor site (Linsel-Nitschke and
Tall 2005), and their effects on cardiovascular outcome have been tested. However,
only a minimal benefit or an increase in heart failure rates was observed in a study
population with diabetes in the “Rosiglitazone Evaluated for Cardiovascular
Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes” (RECORD)
trial (Home et al. 2009). The mean serum creatinine level in the study cohort was
approximately 62 μmol/L (Home et al. 2009). The activation of PPAR-α via
fibrates, which are weak agonists of this receptor (Linsel-Nitschke and Tall
2005), results in reductions in LDL-C and triglycerides, whereas HDL-C plasma
levels are moderately increased (Linsel-Nitschke and Tall 2005; Sahebkar
et al. 2014). The “Veterans’ Affairs High-Density Lipoprotein Intervention Trial”
(VA-HIT) (Tonelli et al. 2004) investigated the effects of the fibrate gemfibrozil in a
cohort of individuals with CKD. Gemfibrozil treatment did not reduce overall
mortality, but the rate of major cardiovascular events and nonfatal myocardial
infarctions (MIs) was significantly reduced in patients with mild to moderate
CKD (Tonelli et al. 2004). Currently, there are no synthetic ligands for PPAR-δ
in clinical use (Sahebkar et al. 2014).
In the secondary prevention of cardiovascular disease, there is evidence that
n3-polyunsaturated fatty acids (n3-PUFAs) are effective (Studer et al. 2005). A
study with HD patients failed to show a reduction in cardiovascular events or death
after treatment with an n3-PUFA (Svensson et al. 2006). However, a significant
reduction of MIs was observed in this patient cohort (Svensson et al. 2006).
Additional pharmacotherapeutic strategies are currently under development.
apoAI-based drugs and reconstituted/engineered HDL particles have been tested
in animal and human studies. Recently, van Capelleveen et al. summarized current
knowledge of these novel therapeutics (van Capelleveen et al. 2014). The human
trials were completed with a limited patient number (<200 patients) and a short
follow-up period (several weeks). However, the clinical impact of these novel drugs
is highly interesting and must be evaluated in larger clinical trials. Several trials are
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currently under way (van Capelleveen et al. 2014); however, the high treatment
costs may limit their use in routine clinical practice. After the promising results in
animal studies, treatment with apoAI mimetics did not improve biomarkers that
were selected to describe HDL function (Watson et al. 2011).
To date, the benefit of apoAI-based therapy for CKD patients remains elusive.
The studies described indicate that with a decline in renal function, lipid-
modulating therapies lose their capacity to prevent the occurrence of cardiovascular
nonfatal and fatal events. Consequently, the lipid compositional and corresponding
functional changes that occur with declining renal function are not fully understood.
In Table 1, the different therapeutic approaches in patients with variable renal
function and the effects on cardiovascular outcome are summarized.
Recent guidelines for the management of lipid disorders in patients with chronic
renal failure recommend lipid-lowering therapy only in patients with CKD who are
not undergoing renal replacement therapy (National Kidney Foundation 2003;
Tonelli and Wanner 2013). The guidelines clearly indicate our inadequate under-
standing of how to address the complex lipid changes in CKD patients.
3.3 Protective Effects of HDL on the Kidney
Based on the current evidence, the causal association between the HDL level, HDL
function, and cardiovascular outcome in CKD patients is not fully understood.
Dysregulated HDL metabolism might be caused by reduced kidney function.
Abnormalities in lipid metabolism enzymes and transport processes have been
described (Hirano 2013; Pahl et al. 2009; Vaziri and Norris 2011). The changes
involve enrichment of free cholesterol, triglycerides, and fatty acids as well as the
depletion of cholesterol esters within HDL. However, there is evidence that HDL
might be an independent protective factor for kidney function. Epidemiologic data
from a multi-study cohort demonstrated an association between a low HDL-C level
and reduced kidney function (Odden et al. 2013). Additional trials addressed the
question of whether HDL-C is associated with the progression of CKD. A recent
study, which included 3,303 patients with CKD stages III to V and a median follow-
up period of 2.8 years, supports the hypothesis that dyslipidemia is independently
associated with rapid renal progression (Chen et al. 2013). Two meta-analyses
suggest that statin therapy has a benefit on GFR and inhibits GFR decline (Fried
et al. 2001; Sandhu et al. 2006). However, other studies found no impact on renal
outcome with statin treatment (Atthobari et al. 2006; Rahman et al. 2008). Focusing
on HDL-C, Baragetti and coworkers observed an association between low HDL-C
and earlier entry in dialysis or doubling of the plasma creatinine in a patient cohort
of 176 subjects with mild to moderate kidney dysfunction (Baragetti et al. 2013).
Moreover, a cross-sectional analysis of 4,925 patients with normal kidney function
strengthened the association between HDL-C and eGFR (Wang et al. 2013).
Confounders (e.g., age, blood pressure, and lipid parameters) influenced the rela-
tionship (Wang et al. 2013). Furthermore, malnutrition and hypoalbuminemia,
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which are frequently present in patients with CKD (Kaysen 2009; Peev et al. 2014),
affected the HDL level and functionality (Khovidhunkit et al. 2004).
Further studies are necessary to determine whether HDL-targeted therapies are
beneficial for renal outcome. The difference in the HDL quantity and functional
quality in CKD patients must be considered. The results of clinical trials, such as
ILLUMINATE (Barter et al. 2007) and HPS2-THRIVE (2013), suggest that
increasing HDL-C plasma levels is not an optimal therapeutic target. Furthermore,
as shown in the “European Prospective Investigation into Cancer and Nutrition”
(EPIC) study and the MESA study, intima/media thickness and cardiovascular
events had a stronger association with HDL particle number compared with HDL
cholesterol levels (Arsenault et al. 2009; El Harchaoui et al. 2009; Mackey
et al. 2012). Figure 2 summarizes the potential protective effects of HDL on kidney
function.
Additional studies that address the structure-dependent functions of the hetero-
geneous HDL particles are necessary to assess the benefit of HDL-increasing
therapy for different disease conditions.
Fig. 2 Interaction of HDL level/function with the kidney. HDL has a pleiotropic protective
function. A decrease in HDL level/function has an impact on the vascular alterations associated
with kidney damage. The decline in kidney function induces/strengthens the decrease in HDL
level/function. For further information and references, refer to the text
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4 Structural and Functional Modifications of HDL in CKD
Patients
In the last several years, HDL and its structural composition in disease conditions,
especially cardiovascular, metabolic, and renal diseases, have been a focus of
experimental research. Compositional changes of the proteome, alterations of the
lipid moiety, and posttranslational modifications of HDL isolated from these patient
cohorts contribute to a lower protective function of the lipoprotein particle
(Annema and von Eckardstein 2013). The following section summarizes the current
knowledge of the HDL changes identified in patients with reduced renal function. It
is important to keep in mind that the investigations were performed in a heteroge-
neous group of patients with different stages of renal failure. Therefore, it is often
difficult to define the role of uremia on the functionality of HDL.
The HDL particle contains hundreds of different lipids and a multitude of
proteins that form a lipoprotein with different shapes, sizes, and densities through-
out its metabolism (Camont et al. 2011; Shah et al. 2013). Because of its amphi-
philic character and the presence of specific binding proteins, HDL serves as cargo
for vitamins, hormones, toxins, and microRNA (Vickers and Remaley 2014). There
is evidence of biological activity for many of the lipid and protein components.
These components can bind to specific receptors and activate signaling pathways in
vascular cells, thereby influencing atherogenesis, thrombosis, apoptosis, oxidative
reactions, endothelial properties, and inflammatory reactions (Calabresi et al. 2003;
Navab et al. 1991; Nofer et al. 2004; Watson et al. 1995). The functions of the
associated proteins and lipids in the vascular wall have been characterized in vitro
and in animal studies, as well as in clinical trials. It has been shown that composi-
tional changes are related to functionality and are influenced by uremic toxins. For
example, (1) the dysregulation of proteins in the HDL metabolism affects HDL
plasma level and cholesterol clearance. Furthermore, (2) changes in HDL apolipo-
protein composition occur, and finally (3) the loss of proteins with a protective
function or (4) the accumulation of substances with a fatal function within HDL
influences its vascular protective properties. The compositional changes may not
only result in a decrease in function but may also lead to increased dysfunction
(Fig. 3), and both are associated with an increased cardiovascular risk profile.
4.1 Dysregulation of Proteins in HDL Metabolism
As discussed in the preceding paragraph, CKD is associated with a decreased
HDL-C plasma concentration and dyslipidemia. The uremic condition is responsi-
ble for the disrupted protein metabolism (Vaziri 2006) due to uremic-induced liver
damage (Yeung et al. 2013). Many proteins important in HDL metabolism are
predominantly produced within the liver, and their production is dysregulated in
uremia. For proper HDL maturation and metabolism, enzymes such as LCAT and
CETP are responsible. Furthermore, diverse receptors on intestinal and peripheral
cells, as well as hepatic cells, are necessary for cholesterol transport via HDL to the
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liver for biliary excretion (Fig. 4). There is evidence that the expression of enzymes
and receptors in HDL metabolism is altered in patients who suffer from kidney
disease. To date, most studies have been completed with CKD stage V patients
dependent on dialysis (ESRD), and less information on enzyme expression has been
obtained from patients prior to dialysis. LCAT is important for HDL maturation. In
ESRD patients, the LCAT enzyme concentration and activity were reduced (Miida
et al. 2003; Moradi et al. 2009; Pahl et al. 2009; Shoji et al. 1992; Tolle et al. 2012).
Fig. 3 Functional vs. dysfunctional HDL particles. Depending on the substances that accumulate
within the HDL, the particle may exert functional or dysfunctional properties
Fig. 4 Dysregulation in HDL metabolism under uremic conditions. # decrease, " increase,$ no
effect. For references, refer to the text
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The association between the plasma levels of cholesterol transport proteins, such as
CETP and CKD, remains unclear. Some studies have failed to show any significant
changes in the CETP protein level or activity (Pahl et al. 2009), whereas other
studies have identified an increased (Dullaart et al. 1993) or decreased (Miida
et al. 2003) CETP level. These controversial data may result from the heterogeneity
of CKD patients and the analysis of different patient subgroups: increased levels
were identified in proteinuric patients (Dullaart et al. 1993), and unchanged or
decreased levels were identified in HD patients with different lengths of minimum
dialysis treatment (minimum of 3 months vs. 1 year) (Miida et al. 2003; Pahl
et al. 2009). The expression of receptors important for RCT appears to be affected
by kidney dysfunction. In nephrectomy animal models, SR-BI (Liang and Vaziri
1999) and ABCA1 (Zuo et al. 2009) receptor expression is decreased. A reduction
of these receptors in humans would subsequently be associated with altered HDL
metabolism in CKD patients.
4.2 Changes of HDL Apolipoproteins (Modifications and Levels)
HDL contains different apolipoproteins. Under uremic conditions, the composition
of the proteins within HDL changes: some protein levels decrease, whereas other
protein levels increase. The main apolipoprotein of HDL under normal physiologi-
cal conditions is apoAI. The presence of altered apoAI levels in CKD patients
remains controversial. Some studies have identified decreased apoAI levels in
dialysis patients (Holzer et al. 2011a; Moradi et al. 2009; Vaziri et al. 1999,
2009), whereas other studies did not identify a significant change in apoAI concen-
tration (Shoji et al. 1992; Tolle et al. 2012). While apoAII and apoCI levels
decreased in CKD patients (Holzer et al. 2011a), apoCII (Holzer et al. 2011a;
Weichhart et al. 2012) and apoCIII (Holzer et al. 2011a) increased. ApoAIV was
not identified in the HDL obtained from healthy subjects, but was detected in
dialysis patients via mass spectrometry analysis (Holzer et al. 2011a). No signifi-
cant difference was found in apoD and apoE levels, whereas apoM levels decreased
(Holzer et al. 2011a). Table 2 summarizes the main apolipoprotein changes in CKD
patients. Currently, most identified changes are based on studies with HD patients.
The discrepancy in apolipoprotein levels may be a result of the heterogeneous
patient population (e.g., CKD stage, time on dialysis, medication, or secondary
disease), different HDL isolation protocols (e.g., one-step vs. multistep ultracentri-
fugation, chromatography, or differentiation between HDL2/3), and different apo-
lipoprotein detection methods (e.g., enzyme-linked immunosorbent assay vs. mass
spectrometry).
In addition to changes in the apolipoprotein levels, modifications of the proteins
within HDL occurred, which were closely connected to altered functionality. To
date, oxidative modifications, carbamylation, and glycosylation have been detected.
These effects may be a consequence of the high level of ROS in patients with renal
failure.
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Patients with CKD suffer from increased reactive oxygen stress (Sung
et al. 2013; Tucker et al. 2013). The pro-oxidant state is multifactorial but is related
to high amounts of uremic toxins. Uremic toxins are directly involved in the
oxidative response, e.g., phenyl acetic acid is a strong inducer of ROS (Schmidt
et al. 2008), and indoxyl sulfate has a dual role that consists of pro-oxidant
properties in the uremic condition and antioxidative properties under normal
physiological conditions (Miyamoto et al. 2011). The increase in highly reactive
radicals contributes to the oxidation of proteins and lipids. For example, the
oxidation of LDL is known to occur in CKD patients (Ribeiro et al. 2012;
Samouilidou et al. 2012). Furthermore, oxidative modifications of apoAI have
been identified (Nicholls et al. 2005; Undurti et al. 2009; Zheng et al. 2004).
ApoAI oxidation is dependent on the binding activity between apoAI and its
receptors ABCA1 (Zheng et al. 2004) and SR-BI (Undurti et al. 2009). Therefore,
ox-apoAI impairs HDL metabolism. In addition, an association between oxidative
modifications of HDL and a higher risk for cardiovascular events in dialysis
patients has been identified (Honda et al. 2012).
Another reactive compound that leads to protein modification is reactive cya-
nate, which induces the carbamylation of proteins. Cyanates emerge from the
degradation of urea or via myeloperoxidase (MPO) at the sites of inflammation
(Holzer et al. 2012; Sirpal 2009). CKD patients are prone to carbamylated proteins
because urea levels are increased in the uremic condition, and these patients
experience increased inflammation. MPO associates with HDL (Nicholls
et al. 2005); thus, HDL proteins in addition to LDL proteins (Apostolov
et al. 2005) become targets for carbamylation. Carbamylation impairs HDL func-
tion by decreasing the cholesterol efflux capacity of HDL from macrophages
(Hadfield et al. 2013; Holzer et al. 2011b).
CKD patients are also prone to glycated protein modifications caused by insulin
resistance, which is a condition that is frequently observed with reduced renal
function (DeFronzo et al. 1981; Kobayashi et al. 2005). Insulin resistance appears
Table 2 Differences in apolipoprotein composition within the HDL in CKD patients compared
with healthy control subjects (" increase, #decrease,$ no change vs. healthy control)
Apolipoprotein
Change in the HDL
in CKD patients References
apoAI #$ Holzer et al. (2011a), Moradi et al. (2009), Shoji
et al. (1992), Tolle et al. (2012), Vaziri et al. (1999),
Vaziri et al. (2009)
apoAII # Holzer et al. (2011a)
apoAIV " Holzer et al. (2011a)
apoCI # Holzer et al. (2011a)
apoCII " Holzer et al. (2011a), Weichhart et al. (2012)
apoCIII " Holzer et al. (2011a)
apoD $ Holzer et al. (2011a)
apoE $ Holzer et al. (2011a)
apoM # Holzer et al. (2011a)
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to be associated with a high burden of oxidative stress. The reduction of oxidative
stress by treatment with a superoxide dismutase/catalase mimetic reduces not only
ROS production but also insulin resistance in a CKD mouse model (D’Apolito
et al. 2010). The modified proteins are advanced glycated end products (AGEs),
which are usually found at high levels in CKD patients. Glycated apoAI is likely an
AGE (Lapolla et al. 2008). It has been speculated that these modified apoAIs have
reduced RCT activity.
Additional proteins are also associated with HDL under physiological and
pathophysiological conditions. Many proteins within HDL have been identified
using a proteomic approach. Some proteins are increased, whereby other proteins
are decreased in HD patients (Holzer et al. 2011a; Weichhart et al. 2012). However,
an association between all of the proteins identified by proteome analysis and HDL
functionality/dysfunctionality in the vessel wall could not be identified. Retinol-
binding protein 4 (RBP4) was detected in the HDL from CKD patients, whereas it
was not found within the HDL of healthy controls (Holzer et al. 2011a). Plasma
levels of RBP4 were increased in dialysis patients (Frey et al. 2008), and the
increase was dependent upon the CKD stage (Henze et al. 2010). Furthermore,
surfactant protein B and α-1-microglobulin/bikunin precursor proteins were signif-
icantly increased in ESRD patients (Weichhart et al. 2012). Transthyretin was not
identified within the HDL from healthy controls, but was detectable in the HDL
from dialysis patients (Holzer et al. 2011a). An overview of the identified proteins
was recently presented (Holzer et al. 2011a; Weichhart et al. 2012).
4.3 Loss of Protective Proteins or Lipids
Oxidative stress participates in the pathogenesis and progression of CKD and was
increased in CKD patients (Mimic-Oka et al. 1999; Puchades et al. 2013). This
results from an imbalance of pro-oxidative and antioxidative signals that is favored
by uremic toxins (Mimic-Oka et al. 1999). Navab et al. postulated that HDL itself
can become pro-inflammatory (Navab et al. 2006). In this condition, serum
lipoproteins are prone to oxidative modification. The enzymes linked to HDL that
have an antioxidative capacity are thought to facilitate oxidative protection. A
higher pro-inflammatory index of HDL in CKD patients resulted in a higher
adjusted death hazard ratio (Kalantar-Zadeh et al. 2007). Furthermore, it was
shown that the in vitro antioxidative function of HDL was impaired in CKD
patients (Moradi et al. 2009). The primary antioxidative HDL-linked enzymes are
PON and glutathione peroxidase, and of these two enzymes, PON is the most
studied one. The PON family consists of three members: PON1, PON2, and
PON3. In contrast to PON2, PON1 and PON3 are secreted in the blood and are
associated within HDL (Macharia et al. 2012). PON1 remains the best-studied
enzyme of this family in cardiovascular disease and kidney dysfunction. In CKD
patients, proteomic analysis did not indicate a significant difference in PON1
compared with healthy individuals (Holzer et al. 2011a), whereas its enzyme
activity was reduced in CKD patients (Dantoine et al. 1998; Kennedy et al. 2013;
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Moradi et al. 2009). The reduction negatively correlated with the CKD stage
(Dantoine et al. 1998). For glutathione peroxidase, decreased concentration and
activity were identified in dialysis patients (Moradi et al. 2009).
The loss of this antioxidative capacity combined with an increased level of
pro-oxidative molecules (see below) may, at least in part, account for the increased
oxidative stress in CKD patients.
A component that contributes to several of the protective functions of HDL is
sphingosine-1-phosphate (S1P) (Nofer et al. 2004, 2007; Schuchardt et al. 2011;
Theilmeier et al. 2006). HDL-associated apoM binds S1P (Christoffersen
et al. 2011). In CKD patients, apoM levels are decreased (Holzer et al. 2011a),
which may lead to higher levels of S1P free from HDL. There are several
indications that non-HDL-bound S1P signaling differs compared with
HDL-bound S1P (Schuchardt et al. 2011).
4.4 Increase of Molecules within HDL with a Fatal Function
in the Vascular Wall
In vitro and in vivo studies and/or clinical trials have identified proteins that
accumulate within HDL. Interestingly, the albumin content in HDL from uremic
patients was elevated, and apolipoprotein displacement may occur (Holzer
et al. 2011a).
The acute phase protein serum amyloid A (SAA), which is secreted by the liver
during inflammation, is primarily transported by HDL within the blood (Uhlar and
Whitehead 1999). In uremic patients, elevated SAA (Holzer et al. 2011a; Tolle
et al. 2012; Weichhart et al. 2012; Zimmermann et al. 1999) is a sign of a chronic
inflammatory status. This is closely related to an increased cardiovascular risk in
humans (Zimmermann et al. 1999). In vitro studies support these findings, as the
accumulation of SAA in HDL was correlated with a reduced anti-inflammatory
capacity of HDL and a pro-inflammatory potential (Tolle et al. 2012; Weichhart
et al. 2012). Furthermore, the cholesterol efflux capacity was decreased when the
SAA level dramatically increased during acute sepsis (Annema et al. 2010). In
addition, SAA accumulation results in the replacement of apoAI and influences
HDL remodeling and metabolism. Nonetheless, the replacement was not identified
in all patient cohorts (Tolle et al. 2012), which may be because of the different
experimental settings. A displacement of other protective proteins during the acute
phase response by SAA was also observed for PON1 and PAF-AH (Van Lenten
et al. 1995). Thus, SAA enrichment within HDL affects the anti-inflammatory
response. Recently, a pro-inflammatory response of SAA-rich HDL in CKD
patients was observed (Tolle et al. 2012; Weichhart et al. 2012). The effects of
SAA accumulation on the cholesterol efflux function of HDL remain controversial.
In some experiments, a reduction of the cholesterol efflux capacity of HDL was
observed if it was enriched with SAA (Artl et al. 2000; Marsche et al. 2007),
whereas other studies found normal efflux capacity even with SAA-rich HDL
(Banka et al. 1995; van der Westhuyzen et al. 2005).
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Furthermore, phospholipases (PLA) associated with cardiovascular mortality are
elevated in uremic patients. For example, lipoprotein-associated PLA (Lp-PLA)
2 was increased in uremic patients (Holzer et al. 2011a). The secreted PLA
2 (sPLA2) concentration and activity were also higher in ESRD patients. This
elevation contributes to excessive oxidative stress in these patients (van der Giet
et al. 2010a).
Dimethylarginines (DMAs), such as asymmetric dimethylarginine (ADMA) and
its structural isomer symmetric DMA (SDMA), have been correlated with cardio-
vascular risk factors. As uremic toxins, they have been associated with cardiovas-
cular outcomes and renal dysfunction (Duranton et al. 2012; Kielstein et al. 2006).
DMAs originate from protein proteolysis and are mainly excreted in the urine.
DMAs influence nitric oxide (NO) synthesis and negatively influence its vascular
protective effects (Bode-Boger et al. 2006). The accumulation of SDMA in HDL
from CKD patients and its association with decreased NO have recently been
demonstrated (Speer et al. 2013).
MPO is another protein associated with the pathogenesis of cardiovascular
disease because of its pro-oxidative and carbamylating potential (Nicholls
et al. 2005; Undurti et al. 2009; Zheng et al. 2004). As discussed earlier, MPO
associates with HDL (Nicholls et al. 2005) and contributes to reduced RCT in
inflammatory diseases (Annema et al. 2010; Zheng et al. 2004). Furthermore,
MPO-derived oxidative products modify apoAI (Hadfield et al. 2013). The
modifications induced by MPO result in a pro-inflammatory HDL particle (Undurti
et al. 2009). In patients with diabetes mellitus type 2, MPO activity was increased in
HDL (Sorrentino et al. 2010). Interestingly, in a CKD cohort, the MPO plasma level
decreased with advancing renal failure (Madhusudhana Rao et al. 2011). Further
studies are necessary to determine the role of MPO in HDL dysfunction in a CKD
cohort.
The HDL from ESRD patients on HD was less effective at accepting cholesterol
from macrophages compared with the HDL from healthy subjects (Holzer
et al. 2011a; Yamamoto et al. 2012). The reverse cholesterol transport may be
affected in uremic patients.
5 Possibility of Functional Restoration of HDL
HDL function has been a recent focus of experimental research. With respect to
weak effects on cardiovascular outcome after an increase of HDL quantity in CKD
patients, HDL function capacity appears important for the design of new therapeu-
tic approaches. Therefore, the question arose whether structural modifications and
associated dysfunctions under uremic conditions are reversible. The best approach
to test this hypothesis in the case of renal function is to study patients after
successful renal transplantation. A limitation of this model is that these patients
often require immunosuppressive drugs, which may affect lipid metabolism and
function (Badiou et al. 2009). Some investigations have attempted to observe
changes in HDL function after renal transplantation. Dantoine and coworkers
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reported that the PON enzyme activity in patients after kidney transplantation was
comparable to that in control subjects, whereas in dialysis patients, it was decreased
(Dantoine et al. 1998). Furthermore, the anti-inflammatory capacity of HDL from
ESRD patients compared with healthy controls increased after successful renal
transplantation (van der Giet et al. 2010b). The observed effect appears to be related
to a decreased SAA level in transplant recipients. Other indicators of the reversibil-
ity of HDL dysfunction are based on studies with chronic heart failure patients. In
this cohort, exercise training, which is an accepted intervention strategy to decrease
cardiovascular risk in heart failure patients, resulted in increased HDL. The authors
demonstrated that changes in HDL function induced by exercise training correlated
with improved endothelial function (Adams et al. 2013).
According to these data it has been suggested that a restoration of HDL is
possible. The lipid metabolism and the composition of different lipoprotein
particles are primarily influenced by the metabolic condition. To date, little infor-
mation is available regarding whether the CKD stage before transplantation is
dependent on the HDL functionality after kidney transplantation or whether a
point-of-no-return exists for functional restoration, vessel damage, and
cardiovascular risk.
6 Laboratory Tests to Measure HDL Function
According to previous clinical and experimental trials, it has become clear that
HDL particle modifications in disease conditions are associated with reduced HDL
function; specific factors that determine HDL functionality remain unclear. It is
known that various structural features are associated with HDL function, which can
be measured by in vitro studies. A limitation arises in the difficulty of comparing
experimental results. The standardization of the experimental design for HDL
isolation, separation of proteins/lipids, sample preparation for proteomic
approaches, and detection methods for components within HDL would help to
overcome certain limitations that may result in discrepancies between findings. In
addition, in vitro functionality assays are very complex and further hamper compa-
rability. The complexity and cost preclude these tests from routine clinical labora-
tory analyses, thus limiting the validation of experimental findings of functionality
in large clinical trials. Standardization, validation, and optimization for high
throughput must first be established.
Recently, an overview of the laboratory tests that measure HDL subclasses
(shape, density) and several HDL functions was described (Eren et al. 2012).
There is a growing need to identify an optimal biomarker that describes HDL
functionality. The development of reproducible, standardized, and validated
methods to assess HDL function for routine use is of substantial interest. The
knowledge regarding individual HDL function can help identify patients who
may benefit from HDL-C increasing therapy or patients with a normal HDL-C
level but at particularly high risk for cardiovascular events.
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Conclusion and Perspective
HDL is a plasma lipoprotein with many pleiotropic protective functions in the
vascular wall, including anti-atherosclerotic properties. Emerging evidence from
clinical and laboratory studies indicates that HDL-C plasma levels in humans do
not adequately represent HDL function. The pleiotropic protective effects of
HDL depend on its composition, which is influenced by pathophysiological
conditions. With the decline of renal function, HDL modifications occur. Evi-
dence suggests that HDL composition, rather than plasma level, may be an
important determinant for its pleiotropic protective function in the vascular
wall. The goal is to identify robust biomarkers that describe HDL functionality
and are measurable in validated, standardized assays that can be used routinely.
Improvement of HDL functionality may serve as an interesting therapeutic
target in the future for populations beyond CKD patients.
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